Free Trial
NASDAQ:ORMP

Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis

Oramed Pharmaceuticals logo
$2.15 -0.01 (-0.46%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$2.14 -0.01 (-0.47%)
As of 06/18/2025 05:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Oramed Pharmaceuticals Stock (NASDAQ:ORMP)

Key Stats

Today's Range
$2.14
$2.20
50-Day Range
$2.11
$2.38
52-Week Range
$1.82
$3.09
Volume
35,339 shs
Average Volume
148,091 shs
Market Capitalization
$87.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Oramed Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
9th Percentile Overall Score

ORMP MarketRank™: 

Oramed Pharmaceuticals scored higher than 9% of companies evaluated by MarketBeat, and ranked 900th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Oramed Pharmaceuticals are expected to decrease in the coming year, from ($0.03) to ($0.19) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oramed Pharmaceuticals is -4.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oramed Pharmaceuticals is -4.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Oramed Pharmaceuticals has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Oramed Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    1.41% of the float of Oramed Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Oramed Pharmaceuticals has a short interest ratio ("days to cover") of 6.4.
  • Change versus previous month

    Short interest in Oramed Pharmaceuticals has recently decreased by 17.19%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Oramed Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Oramed Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.41% of the float of Oramed Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Oramed Pharmaceuticals has a short interest ratio ("days to cover") of 6.4.
  • Change versus previous month

    Short interest in Oramed Pharmaceuticals has recently decreased by 17.19%, indicating that investor sentiment is improving significantly.
  • Search Interest

    Only 2 people have searched for ORMP on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Oramed Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.70% of the stock of Oramed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 12.73% of the stock of Oramed Pharmaceuticals is held by institutions.

  • Read more about Oramed Pharmaceuticals' insider trading history.
Receive ORMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ORMP Stock News Headlines

Oramed Pharm Extends Stock Buyback Program
Gold is soaring. Here’s how to get paid from it
Gold just broke through $3,300… And while the headlines shout about price targets, something even more powerful is happening behind the scenes… Some investors are using a little-known ETF to collect up to $1,152/month from gold's surge. No trading gold futures. No mining stocks. No vaults. Just a simple fund delivering monthly payouts — like clockwork.
See More Headlines

ORMP Stock Analysis - Frequently Asked Questions

Oramed Pharmaceuticals' stock was trading at $2.42 at the beginning of 2025. Since then, ORMP shares have decreased by 11.2% and is now trading at $2.15.
View the best growth stocks for 2025 here
.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) posted its quarterly earnings data on Thursday, May, 15th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.03) by $0.16. The biotechnology company had revenue of $2 million for the quarter.

Oramed Pharmaceuticals' top institutional investors include BML Capital Management LLC (7.39%), Peapod Lane Capital LLC (0.62%), Rathbones Group PLC (0.58%) and Connor Clark & Lunn Investment Management Ltd. (0.21%). Insiders that own company stock include Michael Rabinowitz and Nadav Kidron.
View institutional ownership trends
.

Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oramed Pharmaceuticals investors own include TransEnterix (TRXDW), Compugen (CGEN), Sarepta Therapeutics (SRPT), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD) and Gilead Sciences (GILD).

Company Calendar

Last Earnings
5/15/2025
Today
6/18/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ORMP
Employees
10
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$19.06 million
Pretax Margin
-1,225.60%

Debt

Sales & Book Value

Annual Sales
$1.34 million
Price / Cash Flow
N/A
Book Value
$3.61 per share
Price / Book
0.60

Miscellaneous

Free Float
35,254,000
Market Cap
$87.83 million
Optionable
Optionable
Beta
1.63

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:ORMP) was last updated on 6/19/2025 by MarketBeat.com Staff
From Our Partners